Shrividya Iyer

9.9k total citations · 2 hit papers
76 papers, 4.8k citations indexed

About

Shrividya Iyer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Shrividya Iyer has authored 76 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 9 papers in Surgery. Recurrent topics in Shrividya Iyer's work include Advanced Breast Cancer Therapies (24 papers), Lung Cancer Treatments and Mutations (19 papers) and HER2/EGFR in Cancer Research (13 papers). Shrividya Iyer is often cited by papers focused on Advanced Breast Cancer Therapies (24 papers), Lung Cancer Treatments and Mutations (19 papers) and HER2/EGFR in Cancer Research (13 papers). Shrividya Iyer collaborates with scholars based in United States, United Kingdom and South Korea. Shrividya Iyer's co-authors include Arlene Reisman, Keith D. Wilner, Fiona Blackhall, Yi‐Long Wu, Benjamin Solomon, Tony Mok, Dong‐Wan Kim, Kazuhiko Nakagawa, Jolanda Paolini and Jennifer Tursi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Shrividya Iyer

75 papers receiving 4.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

2014 2.3k citations Benjamin Solomon, Tony Mok et al. New England Journal of Medicine profile →
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

2019 286 citations Hope S. Rugo, Richard S. Finn et al. Breast Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shrividya Iyer United States	24	3.5k	3.0k	1.0k	818	578	76	4.8k
Francesco Di Costanzo Italy	32	2.4k 0.7×	3.5k 1.2×	690 0.7×	715 0.9×	693 1.2×	167	5.0k
Anil A. Joy Canada	31	1.9k 0.6×	2.4k 0.8×	621 0.6×	729 0.9×	481 0.8×	146	4.1k
Umberto Basso Italy	35	1.7k 0.5×	2.1k 0.7×	736 0.7×	1.0k 1.2×	775 1.3×	236	4.7k
Andrew Wardley United Kingdom	36	3.2k 0.9×	6.8k 2.3×	2.4k 2.3×	2.0k 2.5×	645 1.1×	147	9.0k
Jong Seok Lee South Korea	34	3.6k 1.0×	3.4k 1.1×	684 0.7×	1.1k 1.4×	593 1.0×	144	5.2k
Evaristo Maiello Italy	38	1.7k 0.5×	3.7k 1.3×	1.5k 1.5×	1.7k 2.1×	834 1.4×	267	5.8k
Olivia Pagani Switzerland	42	1.5k 0.4×	3.4k 1.1×	1.8k 1.7×	667 0.8×	382 0.7×	159	5.5k
Nofisat Ismaila United States	31	1.9k 0.5×	2.1k 0.7×	1.1k 1.1×	763 0.9×	838 1.4×	76	4.4k
Peter D. Eisenberg United States	34	1.4k 0.4×	2.8k 1.0×	925 0.9×	903 1.1×	1.5k 2.7×	80	5.5k
Masashi Ando Japan	31	954 0.3×	2.0k 0.7×	774 0.8×	688 0.8×	431 0.7×	206	3.6k

Countries citing papers authored by Shrividya Iyer

Since Specialization

Citations

This map shows the geographic impact of Shrividya Iyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shrividya Iyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shrividya Iyer more than expected).

Fields of papers citing papers by Shrividya Iyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shrividya Iyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shrividya Iyer. The network helps show where Shrividya Iyer may publish in the future.

Co-authorship network of co-authors of Shrividya Iyer

This figure shows the co-authorship network connecting the top 25 collaborators of Shrividya Iyer. A scholar is included among the top collaborators of Shrividya Iyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shrividya Iyer. Shrividya Iyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rugo, Hope S., Richard S. Finn, Véronique Dièras, et al.. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment. 174(3). 719–729. 286 indexed citations breakdown →

Taylor‐Stokes, Gavin, et al.. (2019). Abstract P6-18-36: Real world treatment patterns and outcomes of patients receiving palbociclib plus aromatase inhibitor in the United States: Sub-groups analysis based on age, performance status and sites of metastases from the IRIS study. Cancer Research. 79(4_Supplement). P6–18. 1 indexed citations

Mitra, Debanjali, et al.. (2018). Real world treatment patterns associated with palbociclib combination therapy in Germany: Results from the IRIS study. Annals of Oncology. 29. viii110–viii110. 2 indexed citations

Rugo, Hope S., Nicholas C. Turner, Richard S. Finn, et al.. (2018). Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. European Journal of Cancer. 101. 123–133. 59 indexed citations

Mitra, Debanjali, et al.. (2018). Treatment Satisfaction In Women Receiving Palbociclib Combination Therapies For Advanced/Metastatic Breast Cancer. Future Oncology. 15(2). 141–150. 12 indexed citations

Turner, Nicholas C., Richard S. Finn, Miguel Martín, et al.. (2018). Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of Oncology. 29(3). 669–680. 69 indexed citations

Mitra, Debanjali, et al.. (2017). Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Research and Treatment. 166(1). 167–177. 29 indexed citations

Iwata, Hiroji, Seock‐Ah Im, Norikazu Masuda, et al.. (2017). PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients. Journal of Global Oncology. 3(4). 289–303. 96 indexed citations

Harbeck, Nadia, Shrividya Iyer, Nicholas C. Turner, et al.. (2016). Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Annals of Oncology. 27(6). 1047–1054. 114 indexed citations

10.

Mitra, Debanjali, et al.. (2016). Network Meta-Analysis Comparing Palbociclib with Chemotherapies For Treatment of Postmenopausal Women With HR+/ HER2- Advanced/ Metastatic Breast Cancer. Value in Health. 19(7). A714–A714. 2 indexed citations

11.

Wood, Robert, et al.. (2016). Breast cancer specific quality of life in HR+/HER2- advanced/metastatic breast cancer patients in a real-world setting.. Journal of Clinical Oncology. 34(15_suppl). 554–554. 2 indexed citations

12.

Chirila, Costel, Debanjali Mitra, Ann Colosia, et al.. (2016). Efficacy of Palbociclib Combinations Versus Endocrine Therapies in Advanced/ Metastatic Breast Cancer: Network Meta-Analysis. Value in Health. 19(7). A710–A710. 3 indexed citations

13.

Rugo, Hope S., Véronique Dièras, Karen A. Gelmon, et al.. (2016). Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2. Annals of Oncology. 27. vi69–vi69. 6 indexed citations

14.

Solomon, Benjamin, Tony Mok, Dong‐Wan Kim, et al.. (2014). First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. New England Journal of Medicine. 371(23). 2167–2177. 2327 indexed citations breakdown →

15.

Blackhall, Fiona, Enriqueta Felip, Federico Cappuzzo, et al.. (2014). Impact of Crizotinib on Patient-Reported Symptoms and Global Quality of Life (Qol) Compared with Platinum Based Chemotherapy in Phase III Study of Treatment Naïve Advanced Alk-Positive Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology. 25. iv428–iv428. 2 indexed citations

16.

Nokihara, Hiroshi, Vera Hirsh, Fiona Blackhall, et al.. (2013). Phase III Study of Crizotinib vs. Chemotherapy in Advanced ALK+ NSCLC: Patient-Reported Symptoms and Quality of Life. Annals of Oncology. 24. ix43–ix43. 1 indexed citations

17.

Salgia, Ravi, Benjamin Solomon, Alice T. Shaw, et al.. (2012). Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.. Journal of Clinical Oncology. 30(15_suppl). 7596–7596. 16 indexed citations

18.

Iyer, Shrividya, B. Randazzo, Evan Tzanis, et al.. (2011). Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value in Health. 14(1). 177–183. 36 indexed citations

19.

Earnshaw, Stephanie, Rogier Klok, Shrividya Iyer, & Cheryl McDade. (2010). Methylnaltrexone bromide for the treatment of opioid‐induced constipation in patients with advanced illness – a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics. 31(8). 911–921. 22 indexed citations

20.

Iyer, Shrividya & W. Brian Saunders. (2007). Impact of Post-Operative Ileus (POI) on Hospital Length of Stay in Colectomy Surgery Patients. The American Journal of Gastroenterology. 102. S440–S440. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact